Amendment to DM No. 2022-0041 dated January 24, 2022 entitled "Interim Guidelines on the management and administration of Tozinameran COVID-19 mRNA vaccine (nucleoside-modified) [Comirnaty] Pfizer COVID-19 vaccine to pediatric population ages 5-11 y/o
Date: 
Friday, February 4, 2022
Document Type: 
Department Memorandum 2022-0041-A